"One thing I would like to see some guidance on is what to do about patients who use marijuana recreationally," says one urologist.
This article examines current developments in robotic urologic surgery and future directions, including the introduction of alternative surgical robots.
Long-term use of a multivitamin may protect against recurrence of prostate cancer, particularly in those men who have had radical prostatectomy.
Enzalutamide (XTANDI) with androgen deprivation therapy delays the development of metastatic disease in men with M0 castration-resistant prostate cancer compared with ADT alone, according to results from the randomized phase III PROSPER study.
Docetaxel (Taxotere) appears to help improve overall quality of life and delay time for subsequent therapy in men with both non-metastatic and metastatic prostate cancer, according to a new analysis of STAMPEDE trial results.
Adding apalutamide prior to metastases may benefit men with prostate cancer who are no longer responding to androgen deprivation therapy, according to new phase III study findings.
Men undergoing active surveillance for prostate cancer experienced levels of anxiety that were moderate, but that decreased over time, according to results of a large, prospective cohort study presented at the 2017 Society of Urologic Oncology annual meeting in Washington.
“Active surveillance continues to gain traction as a management strategy for low-risk prostate cancer in the United States. However, barriers still exist and challenges remain for both the treating urologist and the patient,” writes J. Brantley Thrasher, MD.
Comorbidity does not affect prostate cancer-specific mortality, according to authors of a large prospective observational study of men in Sweden, published in the Journal of Clinical Oncology (2017; 35:3566-74).
The findings “[raise] the specter that patients could potentially receive different treatments depending on the cell-free DNA platform,” authors of a recent research letter write.